Decernotinib
Decernotinib
Decernotinib (pronunciation: de-ser-no-ti-nib) is an experimental drug that was being developed for the treatment of rheumatoid arthritis. It is a selective inhibitor of Janus kinase 3 (JAK3), a type of enzyme that plays a crucial role in the signaling pathways of various immune cells.
Etymology
The name "Decernotinib" is derived from the Latin word "decerno" which means "to decide" or "to determine", and "tinib", a common suffix for tyrosine kinase inhibitors.
Pharmacology
Decernotinib works by selectively inhibiting the activity of JAK3, thereby reducing the inflammatory response that is characteristic of rheumatoid arthritis. This makes it a potential therapeutic option for patients with this condition.
Clinical Trials
Decernotinib has undergone Phase II clinical trials for the treatment of rheumatoid arthritis. However, the development of the drug was discontinued due to safety concerns.
Related Terms
- Rheumatoid arthritis
- Janus kinase 3 (JAK3)
- Tyrosine kinase inhibitors
- Enzyme
- Immune cells
- Inflammatory response
External links
- Medical encyclopedia article on Decernotinib
- Wikipedia's article - Decernotinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski